AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer's disease
12.May 2014 08:00 CET
- Potential important step towards better diagnosis and clinical management of Alzheimer's disease
- Tau diagnostics complement AC Immune's therapeutic product pipeline
- Piramal Imaging initiates Tau-PET-Imaging tracer development program
- Significant License Agreement signals the importance of the development of Alzheimer's Tau-PET-Imaging tracers